成人肠脑互动障碍患者中回避/限制性摄食障碍症状的患病率与负担:基于人群的研究
该研究基于2023年英美两国具有预设人口学配额的互联网调查,纳入4002名成人,评估肠脑互动障碍(DGBI)与回避/限制性摄食障碍(ARFID)症状的关联。结果显示,DGBI患者ARFID筛查阳性率显著高于无DGBI者(34.6% vs 19.4%;调整OR 1.67;95%CI 1.43-1.94),且随DGBI解剖区域数量增加而升高,DGBI合并ARFID者体重不足、非胃肠道躯体症状、心理困扰及医疗使用均更高。
要点
- DGBI患者ARFID筛查阳性率34.6%,显著高于无DGBI者的19.4%。
- ARFID阳性率随DGBI累及解剖区域数量增加而递增,从19.4%升至61.4%。
- DGBI合并ARFID者体重不足比例更高(7.9% vs 1.5%),整体健康负担更重。
核心结论
- 在成人一般人群中,DGBI患者ARFID筛查阳性常见,且与总体健康负担增加相关。
研究设计与样本
- 2023年在英国和美国开展的基于人群的互联网调查,采用预设人口学配额,纳入4002名成人(中位年龄46岁,范围18-91岁;50%女性)。
主要发现
- 1704名(42.6%)参与者有至少1种DGBI症状;DGBI患者ARFID筛查阳性率为34.6%,无DGBI者为19.4%(调整OR 1.67;95%CI 1.43-1.94),两国结果相似。
- DGBI患者中ARFID九项筛查量表各亚尺度阳性率分别为:缺乏进食兴趣21.5%、感觉性回避18.1%、恐惧不良后果9.9%。
- ARFID阳性率随DGBI解剖区域数量增加而升高:无DGBI为19.4%,1个区域27.7%,2个区域39.5%,3个区域50.0%,4个区域61.4%(P < .001)。
- DGBI合并ARFID者较单纯DGBI者更可能体重不足(7.9% vs 1.5%),非胃肠道躯体症状和心理困扰更重,心理和生理生活质量更低,医疗使用增加。
临床怎么用
- 对DGBI患者应常规筛查ARFID,以便临床医生、营养师和心理学家制定多学科整合照护计划。
局限性
- 研究采用互联网调查和筛查问卷,非临床诊断访谈,可能存在选择偏倚和信息偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Individuals with disorders of gut-brain interaction (DGBI) may experience avoidant/restrictive food intake disorder (ARFID) symptoms. However, extant findings have been limited to specialist neurogastroenterology clinics. We assessed the association between DGBI and ARFID within the adult general population. METHODS: A population-based Internet survey with predefined demographic quotas was conducted across the United Kingdom and the United States in 2023. The survey included the Rome IV diagnostic questionnaire for DGBI, the Nine-Item ARFID Screen, and questions regarding demographics, body mass index, nongastrointestinal somatic symptoms, anxiety and depression, quality of life, and healthcare use. RESULTS: In this study, 4002 adults (median age, 46 [range, 18-91] years; 50% female) completed the survey, of whom 1704 (42.6%) had symptoms compatible with at least 1 DGBI. The prevalence of ARFID-positive screens was significantly higher among participants with DGBI compared with those without DGBI (34.6% vs 19.4%; adjusted odds ratio, 1.67; 95% confidence interval, 1.43-1.94), with similar findings noted in each country. Among participants with DGBI, positive ARFID screens using the Nine-Item ARFID Screen subscale were lack of interest in eating (21.5%), sensory-based avoidance (18.1%), and fear of aversive consequences (9.9%). The presence of ARFID increased with the number of DGBI anatomic regions, ranging from 19.4% in those with no DGBI, 27.7% with DGBI in 1 region, 39.5% for DGBI in 2 regions, 50.0% for DGBI in 3 regions, and 61.4% for DGBI in 4 regions (P < .001). Individuals with DGBI plus ARFID, compared with those with DGBI alone, were significantly more likely to be underweight (7.9% vs 1.5%), have greater nongastrointestinal somatic symptoms and psychological distress, reduced mental and physical quality of life, and increased healthcare use. CONCLUSIONS: Positive ARFID screens are common in DGBI and associated with increased general health burden. Routine screening for ARFID in DGBI will inform the multi-integrated care plan provided by clinicians, dietitians, and psychologists.
引用
- Flack R, Brownlow G, Burton-Murray H, et al. The Prevalence and Burden of Avoidant/Restrictive Food Intake Disorder Symptoms in Adults With Disorders of Gut-Brain Interaction: A Population-Based Study. Gastroenterology. 2025. PMID: 40914329. doi:10.1053/j.gastro.2025.07.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。